Aquatic Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Aquatic Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.66M	Buy	41,528 +37,159	+851%	+$1.93M	0.09%	289
2026 Q1	$210K	Buy	4,369 +2,430	+125%	+$108K	0.01%	972
2025 Q4	$80K	Buy	+1,939	New	+$77.8K	﹤0.01%	1206
2024 Q3	–	Sell	-11,000	Closed	-$205K	–	1357
2024 Q2	$205K	Buy	11,000 +500	+5%	+$9.37K	0.01%	748
2024 Q1	$207K	Buy	10,500 +1,900	+22%	+$37.1K	0.01%	757
2023 Q4	$151K	Buy	+8,600	New	+$141K	﹤0.01%	913
2023 Q2	–	Sell	-600	Closed	-$6K	–	1559
2023 Q1	$6K	Sell	600 -3,300	-85%	-$43.5K	﹤0.01%	1155
2022 Q4	$58K	Sell	3,900 -6,600	-63%	-$96.1K	﹤0.01%	989
2022 Q3	$135K	Buy	+10,500	New	+$120K	0.01%	689
2022 Q2	–	Sell	-200	Closed	-$2K	–	1399
2022 Q1	$2K	Buy	+200	New	+$2.12K	﹤0.01%	968

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Aquatic Capital Management's KNSA Position: Q2 2026 in Review

Aquatic Capital Management increased its Kiniksa Pharmaceuticals (KNSA) stake by 851% in Q2 2026, buying an estimated $1.93M and bringing the position to 41,528 shares worth $2.66M. The position accounts for 0.09% of the portfolio, ranked #289.

Aquatic Capital Management first reported a position in KNSA in Q1 2022 and has held it in 10 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

Aquatic Capital Management held 41,528 shares of Kiniksa Pharmaceuticals worth $2.66M as of Q2 2026.
Aquatic Capital Management bought 37,159 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $1.93M.
Kiniksa Pharmaceuticals made up 0.09% of Aquatic Capital Management's portfolio in Q2 2026, its #289 holding.
Aquatic Capital Management first reported a position in Kiniksa Pharmaceuticals in Q1 2022 and has held it in 10 quarters since.
266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.